These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 36068115)

  • 41. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.
    Schreuer M; Meersseman G; Van Den Herrewegen S; Jansen Y; Chevolet I; Bott A; Wilgenhof S; Seremet T; Jacobs B; Buyl R; Maertens G; Neyns B
    J Transl Med; 2016 Apr; 14():95. PubMed ID: 27095081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
    Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
    Robert C; Flaherty K; Nathan P; Hersey P; Garbe C; Milhem M; Demidov L; Mohr P; Hassel JC; Rutkowski P; Dummer R; Utikal J; Kiecker F; Larkin J; D'Amelio A; Mookerjee B; Schadendorf D
    Eur J Cancer; 2019 Mar; 109():61-69. PubMed ID: 30690294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
    Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [No Abstract]   [Full Text] [Related]  

  • 46. Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy).
    Aglietta M; Chiarion-Sileni V; Fava P; Guidoboni M; Depenni R; Minisini A; Consoli F; Ascierto P; Rinaldi G; Banzi M; Marconcini R; Gueli R; Ferraresi V; Tucci M; Tonini G; Lo Re G; Guida M; Del Vecchio M; Marcon IG; Queirolo P
    Target Oncol; 2021 Nov; 16(6):789-799. PubMed ID: 34755244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.
    Teshima Y; Kizaki M; Kurihara R; Kano R; Harumiya M
    Int J Clin Oncol; 2020 Oct; 25(10):1870-1878. PubMed ID: 32699976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
    Stellato D; Gerbasi ME; Ndife B; Ghate SR; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1227-1237. PubMed ID: 31663466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory
    Hargrave DR; Terashima K; Hara J; Kordes UR; Upadhyaya SA; Sahm F; Bouffet E; Packer RJ; Witt O; Sandalic L; Kieloch A; Russo M; Cohen KJ;
    J Clin Oncol; 2023 Nov; 41(33):5174-5183. PubMed ID: 37643378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
    Dutriaux C; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Saiag P
    Eur J Cancer; 2022 Nov; 175():254-262. PubMed ID: 36170791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
    J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in
    Ferrucci PF; Di Giacomo AM; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Stephens R; Svane IM; Lotem M; Abu-Amna M; Gasal E; Ghori R; Diede SJ; Croydon ES; Ribas A; Ascierto PA;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
    Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.
    Long GV; Weber JS; Infante JR; Kim KB; Daud A; Gonzalez R; Sosman JA; Hamid O; Schuchter L; Cebon J; Kefford RF; Lawrence D; Kudchadkar R; Burris HA; Falchook GS; Algazi A; Lewis K; Puzanov I; Ibrahim N; Sun P; Cunningham E; Kline AS; Del Buono H; McDowell DO; Patel K; Flaherty KT
    J Clin Oncol; 2016 Mar; 34(8):871-8. PubMed ID: 26811525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Algazi AP; Othus M; Daud AI; Lo RS; Mehnert JM; Truong TG; Conry R; Kendra K; Doolittle GC; Clark JI; Messino MJ; Moore DF; Lao C; Faller BA; Govindarajan R; Harker-Murray A; Dreisbach L; Moon J; Grossmann KF; Ribas A
    Nat Med; 2020 Oct; 26(10):1564-1568. PubMed ID: 33020646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract]<